The Federal Trade Commission sent letters to 10 drugmakers April 30 warning them that hundreds of patent listings for 20 drugs are invalid. The agency said “junk” listings keep drug prices high by stalling generic competition.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
